Ligandrol

Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394) -induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes[1][2][3].

Product Specifications

CAS Number

[1165910-22-4]

Product Name Alternative

LGD-4033

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Androgen Receptor; Apoptosis; Caspase; Insulin Receptor

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/LGD-4033.html

Purity

99.93

Solubility

DMSO : ≥ 100 mg/mL

Smiles

FC(F)(F)[C@@H]([C@]1([H])N(C2=CC(C(F)(F)F)=C(C=C2)C#N)CCC1)O

Molecular Formula

C14H12F6N2O

Molecular Weight

338.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Sugumar D, et al. Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration. Assay Drug Dev Technol. 2024 Nov-Dec;22 (8) :397-408.|[2]Ustun Z, et al. Protective Effects of Ligandrol Against Cisplatin-Induced Mouse Muscle Cell Line Toxicity. Pharmaceutical Chemistry Journal, 2025: 1-11.|[3]Hoffmann DB, et al. Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis. J Bone Miner Metab. 2023 Nov;41 (6) :741-751.